anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preeclampsia is a pregnancy-related hypertensive disorder that usually occurs after 20 weeks of gestation. It is characterised by hypertension and proteinuria . Preeclampsia is the leading cause of maternal death, complicating about one-tenth of all pregnancies worldwide . It is the second greatest cause of direct maternal death, accounting for 70,000 maternal mortality globally each year .The burden of preeclampsia and eclampsia is most significant in low- and middle-income countries (LMICs), where hypertensive disorders of pregnancy account for 10-15% of maternal deaths.

Early detection of symptoms, rapid presentation to healthcare facilities, and subsequent management with antihypertensive medications, magnesium sulphate, and delivery of the foetus and placenta improve outcomes in pregnancies complicated by preeclampsia and eclampsia . As a result, ANC visits and intrapartum admission are critical chances for patient counselling Despite the essential relationship between women's awareness of preeclampsia and health seeking behaviour, research on this topic is limited, particularly in underdeveloped countries. Even in developed countries, studies in high-income countries show that only half of patients were counselled about preeclampsia signs and symptoms, despite the fact that counselling by healthcare personnel is related to higher patient knowledge. So there is a gap in studying pregnant women's knowledge and attitudes concerning preeclampsia in underdeveloped countries, particularly Egypt, where studies on this topic are scarce.
BACKGROUND: Airway remodeling is a significant pathological characteristic of chronic obstructive pulmonary disease (COPD). In recent years, hypoxia-inducible factor 1-α (HIF-1α), a member of the hypoxia-inducible factor protein family, has gained attention. However, the potential correlation between HIF-1α and COPD airway remodeling remains unclear.
OBJECTIVE: This study explored the expression patterns of HIF-1α in patients with COPD and its association with airway remodelling. This investigation aims to furnish novel insights for the clinical identification of prospective therapeutic targets for ameliorating COPD-related airway remodelling.
PATIENTS AND METHODS: A total of 88 subjects were included, consisting of 28 controls and 60 COPD patients. Various staining methods were employed to observe the pathological changes in airway tissues. Immunohistochemistry was utilized to detect the expression of HIF-1α and MMP9 (matrix metalloproteinase 9) in airway tissues. Enzyme-linked immunosorbent assay (ELISA) was used to measure the concentration in serum of HIF-1α and MMP9. Computed tomography (CT) airway parameters were measured in all participants to assess airway remodeling. The relationship between serum HIF-1α and MMP9 concentrations and airway parameters was analyzed.
RESULTS: Staining of airway structures in COPD patients revealed significant pathological changes associated with airway remodelling, including mixed cilia and subepithelial fibrosis. The expression of HIF-1α and MMP9 was significantly higher in both human airway tissue and serum compared to controls. Chest CT scans exhibited typical imaging features of airway remodeling and increased airway parameters.
CONCLUSION: The findings suggest a correlation between increased HIF-1α expression and COPD airway remodelling. This study provides novel evidence that HIF-1α may be a potential biomarker for airway remodelling in COPD patients.
Vinorelbine 30 mg/m\^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m\^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
A method and system for designing a dental appliance for an individual. A 3D model including a portion of an individual's face and individual features of the dental arch is displayed on a 3D display. The 3D model includes an augmented reality dental appliance. The 3D model may be manipulated by inputs detected by motion sensors, brain-computer interfaces, both motion sensors and brain-computer interfaces, or other sensors. In response to the gestural neural activity or other input, an augmented reality dental appliance or other aspect of the 3D model is modified. In response to the modified dental appliance or other change, the 3D model is updated and repositioned to provide an updated 3D model. The updated 3D model is displayed on the 3D display. The system and method facilitate modification of augmented reality dental appliances and observation of the resulting aesthetic effects.
The purpose of this Stage I/II intervention study (that is, Stage II for drug use and Stage I for alcohol use and smoking) is to test the efficacy of a brief, computerized motivational intervention for substance abuse among post-partum women. The study will randomly assign 350 post-partum women to either intervention or control conditions, with intervention itself taking approximately 30 minutes in the period before the participant leaves the hospital. Inclusion criteria will include post-partum status, age between 18 and 45, ability to understand spoken English, and meeting criteria for one of the three substance use groups: any illicit drug use in month prior to pregnancy, meeting T-ACE criteria for problem alcohol use, or smoking in past month. Exclusion criteria will include receipt of narcotic pain medication in the past 3 hours, no sleep since giving birth, and inability to provide informed consent (e.g., due to psychosis or other clear cognitive impairment).

Lab-based follow-up will occur at 3- and 6-months postpartum. The primary outcomes will be participant report of frequency of substance use and toxicological analyses of substance use (urinalysis and expired breath CO at 3 and 6 month follow-up, hair analysis at 6-month follow-up). Secondary outcome measures include HIV risk behaviors, receipt of treatment services, motivation to change, self-efficacy, mental health functioning, violence exposure, and consequences related to substance use.
PURPOSE:The titled composition containing an etherified starch as a main compo nent. CONSTITUTION:A composition for preventing and remedying decubitus compris ing >=40wt%, preferably 80-99wt% based on total amount of an etherified starch (one obtained by etherifying hydroxyl group of starch may be used burt etherified starch obtained by treating starch with epichlorohydrin is preferably) as a main component. The composition may contain other medicinal components, medical auxiliaries and a carrier corresponding to intended purposes. A magne sium compound may be added to the composition with respect to water-vapor prevention of the composition and the content of the compound is 0.5-50wt%. The composition is preferably used in a powdery state and the particle size of the etherified starch is size wherein the whole particles have <=100 microns, preferably <=50 microns. EFFECT:Having extremely high moisture absorption and good slipperiness and improved preventing and remedying effects on decubitus.
Based on in vitro data, PF-06648671 was predominantly metabolized by CYP3A and therefore there is a potential risk that PF-06648671 PK will be affected by co-administered drugs that can inhibit CYP3A activity. This is a clinical drug interaction study to evaluate this potential drug interaction in human. In this study, healthy volunteers will take a single dose of 25 mg PF-06648671 in period 1 followed by at least 7 day washout. In period 2, same subjects will take 200 mg itraconazole oral solution once a day for 3 days, followed by co-administration of 200 mg oral solution and a single dose of 25 mg PF-06648671 on day 4 which are dosed approximately one hour apart with itraconazole is given first. The PF-06648671 PK will be collected 0-48 hours after dose in period 1 and 0-240 hrs in period 2. Safety will also be monitored throughout both periods.
The present invention is directed to a platform for new bispecific targeting agents using liposomes or nanoparticles as linkers. The bispecific targeting agent can bind two different cell types, each via a separate targeting moiety. Said targeting agents can be used to induce specific biological effects in the cells such as cell proliferation or cell activation which can be used in some instances to destroy the other bound cells. Any cell that can be targeted can be subject to targeting. For example, the cell types that may be recruited by the bispecific targeting agent may be both human or one of the cells may be human and the other an infected cell or it can be an infectious agent. The platform is based on an empty nanoparticle or liposome conjugated to two or more targeting moieties, bound to the nanoparticle/liposome at defined ratios that may be other than 1:1. Such, compositions provide for specific binding to each cell type. This bispecific targeting agent can further be linked to growth factors or cytokines to further potentiate the effect of the bispecific targeting agent as a therapeutic or to exert a specific biologic effect on one or both cells being targeted.
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 (the day of first vaccination is defined as Day 1) and Day 29 in healthy adults ≥ 18 and \< 50 years of age. The study will consist of two dosing groups of HydroVax-002 YFV vaccine to be enrolled sequentially. Each dose group will consist of 10 individuals who receive HydroVax-002 YFV, as well as 5 total subjects who receive placebo. Each dose-group will include a sentinel subgroup consisting of 3 vaccine and 1 placebo recipient. In each of the two (1 mcg and 5 mcg) dose phases, enrollment is halted after the dose 1 vaccination of the sentinel subgroup. Following assessment of safety and reactogenicity data of Group 1 by the Safety Monitoring Committee (SMC), the vaccine dose will be increased to 5 mcg for Group 2.
The 2nd group (n=50) receives surgical method (laparoscopic MGB). These patients pass through additional pre-operation examination (blood tests and electrocardiography, esophagogastroscopy, ultrasound, and other necessary standard methods).
To evaluate the possible changes in microbiota and cognitive skills after consumption of roasted peanuts and peanut butter, a three-arm parallel-group randomized, and controlled study is being carried out. Ninety healthy college students were enrolled, according to the sample size estimated. Blood, urine, feces and saliva are being drawing at baseline, 3 and 6 months. Peripheral blood mononuclear cells are being extracted to evaluate the metabolic changes caused by the proposed nutritional interventions. To assess diet and physical activity a 151-items food frequency questionnaire plus a 7-day dietary record and a validated questionnaire Minnesota are being used. To determinate the effects of the intervention on body composition and vascular risk factors, anthropometric, biochemical and clinical measurements are being collected. Possible changes in cognitive skills will be determined from a validated cognitive questionnaire (WAIS-IV, Wechsler Memory Scale-IV (WMS-IV), COPE and HAD). To evaluate inflammation and metabolic status before and after intervention, levels of hormones and signaling molecules will be analyzed in blood samples. The effect of roasted peanut and peanut butter consumption on microbiota will be assayed through identification and quantification of polyphenols and short-chain fatty acids in biological samples, as well as the gut microbiota characterization from DNA extraction.
Marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment (so-called spontaneous quitting). This study will use two self-report questionnaires to collect information on the socio-demographic characteristics, marijuana use history, most difficult marijuana quit experience, and marijuana craving from a convenience sample of 1230 adult, non-treatment-seeking marijuana users. The questionnaires take 45-60 minutes to administer. Data will be analyzed for patterns and correlations among the characteristics of the quit attempt, including any withdrawal symptoms, quitting strategies used, and its success. The marijuana craving data will be analyzed to evaluate the validity of this measure of marijuana craving. There are no direct benefits to subjects from study participation. The scientific benefit is an improved understanding of spontaneous quitting of marijuana use, which may lead to improved interventions for marijuana users in the future. There are no physical risks to subjects. There are risks of anxiety or embarrassment while taking the questionnaire and of loss of confidentiality of sensitive information collected about subjects.
1. A method for delivering an active agent to the lungs of a human patient, comprising delivering an aerosolized active agent formulation at an inspiratory flow rate of less than 17 liters per minute. 2. The method of claim 1 wherein the inspiratory flow rate is less than or equal to 10 liters per minute. 3. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent in dry powder form. 4. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent in nebulized form. 5. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent in admixture with a propellant. 6. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent solution. 7. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent suspension. 8. The method of claim 1 wherein the aerosolized active agent formulation comprises an active agent slurry. 9. The method of claim 1 wherein the active agent is selected from the group consisting of cyclosporin, parathyroid hormone, follicle stimulating hormone, alpha-1antitrypsin, budesonide, human growth hormone, growth hormone releasing hormone, interferon alpha, interferon beta, growth colony stimulating factor, leutinizing hormone releasing hormone, calcitonin, low molecular weight heparin, somatostatin, respiratory syncytial virus antibody, erythropoietin, Factor VIII, Factor IX, ceredase, cerezyme and analogues, agonists and antagonists thereof. 10. A method for delivering insulin to the lungs of a human patient, comprising delivering an aerosolized insulin formulation at an inspiratory flow rate less than 17 liters per minute.
Press the actuator button firmly, allowing Pain Ease to spray from the can. 

Hold the can upright while spraying.

PRE-INJECTION & MINOR SURGICAL TOPICAL ANESTHESIA: Have all necessary equipment ready and prepare the procedure site per facility’s protocol. Hold the can upright, 3 to 7 inches (8 to 18 cm) from the procedure site, about a can’s length away. Spray steadily 4 to 10 seconds or until the skin begins turning white, whichever comes first. Do not spray longer than 10 seconds. After spraying the site, immediately perform the procedure. The anesthetic effect of Pain Ease lasts about one minute. Reapply if necessary.  


*Apply petrolatum to protect the adjacent area for minor surgical procedures.  
  
Other Application Methods for Pre-Injection Anesthesia:

COTTON APPLICATION: Have necessary equipment ready. Prepare the procedure site per facility’s protocol. Spray Pain Ease into a cup, for about 10 seconds, or until 5 ml of the product has accumulated. Place a cotton ball, cotton swab or gauze into the cup until it is well saturated with Pain Ease and there is no visible product left in the cup. Cotton may also be directly sprayed for 10 seconds to achieve saturation. Immediately after saturation, apply the cotton to the site. Hold firmly on the site for 5-15 seconds and immediately perform the procedure. Reapply as needed. Use this application method on intact skin. If the skin is breached use this application method only with STERILE, disposable cotton balls, cotton swabs or gauze.

TEMPORARY RELIEF OF MINOR SPORTS INJURIES: The pain of bruises, contusions, swelling, minor sprains, cuts and abrasions may be controlled with Pain Ease. The amount of cooling depends on the dosage. Dosage varies with duration of application. The smallest dose needed to produce the desired   
effect should be used. The anesthetic effect of Pain Ease lasts about one minute. This time interval is usually sufficient to help reduce or relieve the initial trauma of the injury. Hold the can upright, 3 to 7 inches (8 to 18 cm) from the target area, about a can’s length away. Spray steadily 4 to 10 seconds or until the skins begins turning white, whichever comes first. Do not spray longer than 10 seconds. Reapply if necessary.
In this article, the impact of radiofrequency electromagnetic field (RF-EMF) exposure from a simulated base station for the 5G New Radio (5G NR) telecommunication on rats was studied. The base station affects all age groups of the population, thus, for the first time, the experiment was conducted on male Wistar rats of three different ages (juvenile, adult, and presenile). The base station exposure parameters were chosen according to ICNIRP recommendations for limiting the exposure to radiofrequency electromagnetic field: frequency 2.4 GHz with an average specific absorption rate of 0.0076 W/kg and 0.0059 W/kg over the whole body of experimental animals. Throughout the experiment, body weight was examined weekly, and the dynamics of body weight gain was monitored. Rectal and skin surface temperature on the right hind limb was monitored weekly. Testing in the Morris water maze was performed during the last, Week 5, of RF-EMF exposure. After euthanasia, organ weights were determined in experimental and control animals. None of the investigated parameters did show any statistically significant differences between exposed and control animals of the same age. The data obtained can be used to assess the possible consequences of chronic exposure to RF-EMF from 5G NR base stations.
Neovascularization is the hallmark of retinopathy of prematurity (ROP). Early growth response 1 (EGR1) has been reported as an angiogenic factor. This study was conducted to probe the regulatory mechanism of EGR1 in neovascularization in ROP model mice. The ROP mouse model was established, followed by determination of EGR1 expression and assessment of neovascularization [vascular endothelial growth factor-A (VEGF-A) and pigment epithelium-derived factor (PEDF)]. Retinal vascular endothelial cells were cultured and treated with hypoxia, followed by the tube formation assay. The state of oxygen induction was assessed by real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot assay to determine hypoxia-inducible factor 1-alpha (HIF-1A). The levels of microRNA (miRNA)-182-5p and ephrin-A5 (EFNA5) in tissues and cells were determined by RT-qPCR. Chromatin immunoprecipitation and dual-luciferase assay were used to validate gene interaction. EGR1 and EFNA5 were upregulated in the retina of ROP mice while miR-182-5p was downregulated. EGR1 knockdown decreased VEGF-A and HIF-1A expression and increased PEDF expression in the retina of ROP mice. In vitro, EGR1 knockdown also reduced neovascularization. EGR1 binding to the miR-182-5p promoter inhibited miR-182-5p transcription and further promoted EFNA5 transcription. miR-182-5p downregulation or EFNA5 overexpression averted the inhibition of neovascularization caused by EGR1 downregulation. Overall, EGR1 bound to the miR-182-5p promoter to inhibit miR-182-5p transcription and further promoted EFNA5 transcription, thus promoting retinal neovascularization in ROP mice.
Stressful encounters, ranging from daily hassles to major life events, are ubiquitous in our everyday lives and are often responsible for significant changes in affective and cognitive processes. In various physical diseases, including hereditary angioedema (HAE) due to C1 inhibitor deficiency, stressful events are also frequently reported by patients to trigger acute attacks. These include physical stress (such as injury, pain, viral infections, medical and dental procedures, and surgery) and mental stress (including stress from life events and school or work, clinical depression, and anxiety), or stress originating from the disease itself, especially if the disease is characterized by an unpredictable nature like HEA that directly impacts patients' choices in everyday life. Available literature related to the link between HAE and stress is limited and mainly focused on the patients' narratives. Self-reported data suggested that the main HAE trigger seems to be stress, followed by physical trauma. These observations suggest analyzing the perceived psychological effects consequent to stress exposure together with biochemical and physiological responses. The effect of stress could be systematically examined in a laboratory environment using a standardized protocol that reliably induces stress and activates major stress responses in experimental contexts. A reliable test to induce stress in HAE patients combining these two aspects may be the Socially Evaluated Cold Pressor Test (SECPT). SECPT is an extension of the classical Cold Pressor Test, in which participants immerse one of their hands in ice water with socio-evaluative elements, and has been proven to be a highly efficient tool for experimental stress induction in humans. Adding social-evaluative elements to the original physical stress boosted the cortisol response, making the SECPT a well-established standard protocol in human stress research that may represent an efficient alternative to other established protocols, such as the Trier Social Stress Test, a 'gold standard' in the field. A recent review confirmed that exposure to the SECPT leads to changes in subjective feeling, and triggers a significant sharp increase in systolic and diastolic blood pressure. The present study aims to evaluate objective and subjective stress responses between HAE patients and healthy controls due to SECPT. Moreover, as secondary aims, the study wants to investigate if the presence of anxiety and depressive symptoms, as well as body appreciation, trust in the body, pain catastrophizing, pain interference, and pain intensity, affect or mediate stress response in patients and healthy subjects similarly or differently.
Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.